Drug Trial Radar · NCT06073821
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
652
Planned (sponsor's estimate)
Start
Nov 11, 2023
Primary completion
Feb 2032
Study completion Dec 2032
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Conditions
- CLL
Interventions
SonrotoclaxDrug
Administered orally
ZanubrutinibDrug
Administered orally
VenetoclaxDrug
Administered orally
ObinutuzumabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Progression Free Survival (PFS)Time frame: Up to approximately 9 years
- Cohort 1: Rate of Undetectable Measurable Residual DiseaseTime frame: Up to one and a half years
Locations
201 sites in 21 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology, Llc
Anchorage, Alaska
City of Hope National Medical Center
Duarte, California
University of California San Diego (Ucsd) Moores Cancer Center
La Jolla, California
Valkyrie Clinical Trials
Los Angeles, California
UCLA Department of Medicine Hematologyoncology
Los Angeles, California
Chao Family Comprehensive Cancer Center
Orange, California
Stanford Medicine
Palo Alto, California
University of Colorado Cancer Center
Aurora, Colorado
Medstar Georgetown University Hospital
Washington D.C., District of Columbia
Mount Sinai Medical Center Braman Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Southeastern Regional Medical Center
Newnan, Georgia
Northwestern University
Chicago, Illinois
Illinois Cancercare, Pc
Peoria, Illinois
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Mission Cancer and Blood
Waukee, Iowa
The University of Kansas Cancer Center
Westwood, Kansas
Norton Cancer Institute Pavilion
Louisville, Kentucky
Ochsner Clinic Foundation
New Orleans, Louisiana
University of Minnesota
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Columbia University Medical Center
New York, New York
Optum Medical Care, Pc
Westbury, New York
University of North Carolina At Chapel Hill
Chapel Hill, North Carolina
Atrium Health Levine Cancer Institute (Lci)
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
The James Cancer Hospital and Solove Research Institute At Ohio State University
Columbus, Ohio
Oncology Associates of Oregon Willamette Valley Cancer Center
Eugene, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Scri Tennessee Oncology Chattanooga
Chattanooga, Tennessee
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Cancer Institute
Richmond, Virginia
Vcu Health System Massey Comprehensive Cancer Center
Richmond, Virginia
Fred Hutchinson Cancer Research Center
Seattle, Washington
Gunderson Health System
La Crosse, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Showing 40 of 201 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.